^
Association details:
| Biomarker: | miR-155 deletion + FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Vanflyta (quizartinib) (FLT3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LOSS OF MIR-155-5P INCREASED THE TREATMENT SENSITIVITY TO CHEMOTHERAPY AND FLT3 INHIBITORS IN FLT3-ITD+AML VIA GLYCOLYSIS BLOCKING BY TARGETING PIK3R1
Published date:
05/14/2020
Excerpt:
The FLT3 tyrosine kinase inhibitors such as midostaurin and quizartinib (AC220) have been successfully used for patients with FLT3 mutations in combination with chemotherapy in both the first-line and salvage therapy…. In conclusion, loss of miR-155 increased the treatment sensitivity to both chemotherapy and FLT3 inhibitors in FLT3-ITD+AML via glycolysis blocking by targeting PIK3R1.
Secondary therapy:
Chemotherapy
